Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

190.17 -0.91 (-0.48%)
Streaming Delayed Price Updated: 3:18 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a... 
Via MarketMinute
Topics Bonds Economy Government
Why Johnson & Johnson Could Be the Ultimate Dividend King
Johnson & Johnson has increased its dividend every year for 63 consecutive years. It doesn't want to stop. 
Via The Motley Fool
Is Palantir Technologies Stock a Buy Now?
The stock is once again nearing an all-time high, but the valuation is untenable. 
Via The Motley Fool
Topics Artificial Intelligence
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and... 
Via MarketMinute
Topics Economy Intellectual Property
US Government Braces for Unprecedented Shutdown: Economic Fallout Looms as Deadline Nears
As the clock ticks towards midnight on September 30, 2025, the United States government stands on the precipice of a highly imminent and seemingly unavoidable shutdown. With just days left until the... 
Via MarketMinute
Topics Economy Government Workforce
The Phoenix Play: Unearthing Beaten-Down Stocks for a Powerful Comeback
In the dynamic landscape of financial markets, the allure of finding deeply discounted assets with a strong potential for recovery remains a cornerstone of successful investment strategies. As of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
Jabils AI-Driven Boom Has Begun: News Highs are Coming
Jabil is well-positioned to benefit from the long-term demand driven by AI and its impact on technology at all levels. Analysts are leading this market higher. 
Via MarketBeat
Topics Artificial Intelligence
Could This Single Dividend King Make Your Portfolio Worth $1 Million in 20 Years?
There is a lot to like about this healthcare company, but that goal might be beyond its powers. 
Via The Motley Fool
Topics Intellectual Property
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson (NYSE: JNJ) revealed 17 unusual trades. 
Via Benzinga
What's Driving the Market Sentiment Around Johnson & Johnson?
Johnson & Johnson's (NYSE: JNJ) short interest as a percent of float has risen 17.95% since its last report. According to exchange reported data, there are now 22.05 million shares sold short, which is... 
Via Benzinga
US Stocks Grapple with Quarter-End Jitters, Two-Day Losing Streak Tests Market Resolve
New York, NY – September 25, 2025 – As the third quarter of 2025 rapidly approaches its conclusion, U.S. stock markets are navigating a challenging period, marked by a two-day losing streak that... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Market Tremors: Dow, S&P 500, and Nasdaq Endure Third Straight Day of Losses Amidst Economic Headwinds
New York, NY – September 25, 2025 – Major U.S. stock indices, including the Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite, have registered their third consecutive day of declines,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Johnson & Johnson (NYSE:JNJ) Shows Strong Technical Setup for Potential Breakout
Johnson & Johnson (JNJ) shows a strong technical uptrend and a high-quality consolidation pattern, signaling a potential breakout as it trades near 52-week highs. 
Via Chartmill
These 3 Dow Stocks Are Set to Soar in 2025 and Beyond
The proverbial planets are aligning for each of their underlying companies. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years
Not only have these stocks raised their dividends consistently, but they also offer above-average yields. 
Via The Motley Fool
Topics Economy
Kenvue Bounces Off Record Low: A Deep Dive into its Rebound and Future Prospects
Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence... 
Via MarketMinute
Topics Government Product Recall
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies
A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program. 
Via Benzinga
Johnson & Johnson Is Attacking 2022 Highs
Johnson & Johnson is attacking 2022 highs, as we see it rising impulsively, ideally unfolding a five-wave bullish cycle of different degrees by the Elliott wave model. 
Via Talk Markets
Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’
Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry. 
Via Stocktwits
Topics Economy Government Lawsuit
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes. 
Via Benzinga
Jabil Set For Major AI Growth As Other Segments Falter: Analyst
Jabil Inc. to report fiscal Q4 earnings; AI and cloud revenue key factors for outlook. Analyst expects conservative guidance. 
Via Benzinga
Topics Artificial Intelligence
Evolving Investment Strategies for an Uncertain Market
In an era marked by persistent inflation, fluctuating interest rates, geopolitical tensions, and rapid technological shifts, investors are facing an increasingly complex and unpredictable financial... 
Via MarketMinute
Topics Bonds ETFs Economy
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors
Johnson & Johnson will halt international sales of its Linx reflux device, sparking concern among surgeons over limited options for GERD patients. 
Via Benzinga
Beyond The Numbers: 10 Analysts Discuss Johnson & Johnson Stock
 
Via Benzinga
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety? 
Via The Motley Fool
Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism
Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears. 
Via Benzinga
Topics Government Lawsuit
Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?
Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks. 
Via Stocktwits
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.